Blood Advances

Article	Citations
Smith CC, Levis MJ, Perl AE, et al. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022;6(7):2144-2155.	195
Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6)	191
Complete absence of GLUT1 does not impair human terminal erythroid differentiation	142
Steroid tapering after GVHD Rx: not too fast, not too slow	141
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A	136
Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study	132
Addressing and overcoming disparities in GVHD	127
Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report	120
Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia	113
Predictors of liver disease outcomes in individuals with hemophilia and HCV infection	113
On a collision course: SARS-CoV-2 variants and CAR T cells	112
Pirillo C, Birch F, Tissot FS, et al. Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness. Blood Adv. 2022;6(10):3126-3141.	112
Campbell BA, Dobos G, Haider Z, et al. International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies. Blood Adv. 2023;7(21):	105
Kennedy VE, Wong C, Huang C-Y, et al. Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. Blood Adv. 2021;5(23):5344-5348.	101
Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia	99
Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL	98
LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling	93
Molecular subclusters of follicular lymphoma: a report from the United Kingdom’s Haematological Malignancy Research Network	92
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination	91
Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry	90
Megakaryocyte/platelet-derived TGF-β1 inhibits megakaryopoiesis in bone marrow by regulating thrombopoietin production in liver	88
BCL11A promotes myeloid leukemogenesis by repressing PU.1 target genes	86
Low neutralizing activity of AZD7442 against current SARS-CoV-2 Omicron variants in patients with B-cell malignancies	86
Structural analysis of platelet fragments and extracellular vesicles produced by apheresis platelets during storage	85
Matrix stiffness controls megakaryocyte adhesion, fibronectin fibrillogenesis, and proplatelet formation through Itgβ3	84

Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulation	84
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children	84
A novel 3D culture model recapitulates primary FL B-cell features and promotes their survival	83
International study of treatment efficacy in SS shows superiority of combination therapy and heterogeneity of treatment strategies	83
Desensitization to calaspargase pegol appears to be less successful than pegaspargase	79
Bite-size introduction to canine hematologic malignancies	76
Best but not perfect: indirect measure of low iron stores	76
Converting IMPROVE bleeding and VTE risk assessment models into a fast-and-frugal decision tree for optimal hospital VTE prophylaxis	76
Longitudinal clinical data improve survival prediction after hematopoietic cell transplantation using machine learning	75
Selective modulation of activated protein C activities by a nonactive site–targeting nanobody library	73
Transfusion therapy for sickle cell disease: what’s new?	72
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model	69
Genome-wide whole-blood transcriptome profiling across inherited bone marrow failure subtypes	66
Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years	66
Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi	64
The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool	63
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemia	63
Sickle cell disease is a risk factor for transplant-associated thrombotic microangiopathy in children	63
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia	63
Complement C5 inhibition in early onset HELLP syndrome	62
Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors	61
COVID-19 vaccination during therapy in relation to COVID-19 death in CLL	61
Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia	60
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel	60
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea	60
CD58 loss in tumor cells confers functional impairment of CAR T cells	60
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries	59
Long term outcome of Hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse	59
Applying CRISPR-Cas9 screens to dissect hematological malignancies	58
Cortisol in Sickle Cell Disease: A Systematic Review and Meta-Analysis	58
Pirfenidone for the treatment of bronchiolitis obliterans syndrome related to chronic graft-versus-host disease	58
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis	57
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell–mediated tumor responses	57
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in lymphoma patients	57
Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703	57
ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV	56
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients	56
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma	56
Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis	55
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML	55
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes	55
Characteristics and outcomes of patients with CLL and CDKN2A/B deletion by fluorescence in situ hybridization	55
Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia	55
Code status transitions in patients with high-risk acute myeloid leukemia	54
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium	54
Fanconi anemia neuroinflammatory syndrome: brain lesions and neurologic injury in Fanconi anemia	54
Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities	53
CAR T-cell therapy for secondary CNS DLBCL	53
Impaired exercise capacity in post–COVID-19 syndrome: the role of VWF-ADAMTS13 axis	53
Return emergency department visits for recurrent pulmonary embolism symptoms in children and adolescents	52

Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts	52
Ibrutinib increases miR-181a/b in leukemic cells from patients with chronic lymphocytic leukemia	52
Association between hemoglobin values and VWF assays: a multicenter investigation	52
FBXW7β isoform drives transcriptional activation of the proinflammatory TNF cluster in human pro-B cells	51
G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL	51
U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes	51
Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease	51
Cleavage of talin by calpain promotes platelet-mediated fibrin clot contraction	51
Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms	50
Epigenetic features support the diagnosis of B-cell prolymphocytic leukemia and identify 2 clinicobiological subtypes	50
Another step toward frontline BTK inhibitor therapy in MCL	50
EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress	50
Evaluating complement dysregulation in livedoid vasculopathy using a functional assay	50
D-dimer for patients on VKA vs DOAC: impact on the validity of D-dimer to make decision for extended anticoagulation	49
Dasatinib-induced spleen contraction leads to transient lymphocytosis	49
Distinguishing STAT3/STAT5B-mutated large granular lymphocyte leukemia from myeloid neoplasms by genetic profiling	49
Graft-versus-host disease may cause pulmonary restriction, but not all restriction is graft-versus-host disease	48
Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the Fondazione Italiana Linfomi MCL0208 trial	48
Hasselbalch HC, Kristiansen MH, Kjær L, et al. CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities. Blood Adv. 2024;8(3):681-682.	48
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5	48
Pharmacokinetics, pharmacodynamics, safety, and efficacy of crizanlizumab in patients with sickle cell disease	47
Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL	47
AMPK drives both glycolytic and oxidative metabolism in murine and human T cells during graft-versus-host disease	47
Myb drives B-cell neoplasms and myeloid malignancies in vivo	46
Donor age contributes more to the rheological properties of stored red blood cells than donor sex and biological age distribution	46
High frequency of central nervous system involvement in transformed Waldenström macroglobulinemia	46
Adaptation of Serious Illness Care Program to be delivered via telehealth for older patients with hematologic malignancy	46
Long-term data needed for SCD gene therapy	46
Interpretation of Response in BOS-the Definitions Remain Key	45
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients	45
Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities	45
Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS	45
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera	45
Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study	45
Implementation of hospital-based sickle cell newborn screening and follow-up programs in Haiti	45
An αIIbβ3 ligand-mimetic murine monoclonal antibody that produces platelet activation by engaging the FcγIIa receptor	44
Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning	44
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a Phase I trial.	44
Efficacy and Safety of BCMA Nanobody CAR-T Cell Therapy in Relapsed or Refractory Plasma Cell Myeloma	44
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy	43
Longitudinal analysis of cardiac abnormalities in pediatric patients with sickle cell anemia and effect of hydroxyurea therapy	43
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis	43
Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning	42
Severe Parvovirus B19 Infection in Patients with Sickle Cell Disease Hospitalized in Intensive Care Unit	42
Commentary on the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD: reflections based on recent contemporary test data	42
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia	42
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease	42
Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma	41
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma	41
Long live the red blood cell: biotin tagging in SCD	41
The ISHLT chronic lung allograft dysfunction consensus criteria are applicable to pulmonary chronic graft-versus-host disease	41
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience	41
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma	41
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia	41
Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression	41
RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo	41
Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations	40
HLA reduction of human T cells facilitates generation of immunologically multicompatible cellular products	40
Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma	40
Tumor-associated antigen–specific T cells with nivolumab are safe and persist in vivo in relapsed/refractory Hodgkin lymphoma	40
A 69 long noncoding RNA signature predicts relapse and acts as independent prognostic factor in pediatric AML	40
Bridging therapy before axi-cel for lymphoma	39
Digital pathology in pediatric nodular lymphocyte-predominant Hodgkin lymphoma: correlation with treatment response	39
Factor XI inhibitors: a new class of anticoagulants	39
Should we move to a genomic classification of neutrophilic myeloid neoplasms?	39
The American Society of Hematology Health Equity Compendium: examining health equity across the Blood journals	39
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?	39
Commentary on the 2021 ASH Guidelines on use of anticoagulation in patients with COVID-19 being discharged from the hospital	39
Combinatorial targeting of epigenome-modifying enzymes with decitabine and RN-1 synergistically increases HbF	38
Cellular and biochemical heterogeneity contributes to the phenotypic diversity of transfusion-dependent β-thalassemia	38
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma	38
Cutaneous dysbiosis characterizes the post–allogeneic hematopoietic stem cell transplantation period	38
Immune profiling after allogeneic hematopoietic cell transplantation in pediatric acute myeloid leukemia	38
Deciphering the regulatory landscape of murine splenic response to anemic stress at single-cell resolution	38
Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial	38
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial	38
Presentation of CXCL12γ by heparan sulfate proteoglycans activates CXCR4 without desensitization in normal and malignant B cells	38
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma	38
Eculizumab for refractory thrombosis in antiphospholipid syndrome	37
Daratumumab for immune thrombotic thrombocytopenic purpura	37

Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia	37
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation	37
Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy	37
Gioacchino E, Koyunlar C, Zink J, et al. Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish. Blood Adv. 2021;5(13):2687-2700.	37
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease	37
T-cell malignancies with anti-CD19 chimeric antigen receptor T-cell therapy	37
Dual ASXL1 and CSF3R mutations drive myeloid-biased stem cell expansion and enhance neutrophil differentiation	37
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom	36
Efficacy and safety of dapsone in adult primary immune thrombocytopenia	36
Prognostic impact of patient-reported symptoms in multiple myeloma	36
Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy	36
Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis	36
Outpatient subcutaneous alemtuzumab is feasible and safe for aplastic anemia and is associated with high response rates	36
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas	36
Lineage switching of the cellular distribution of BRAF V600E in multisystem Langerhans cell histiocytosis	36
TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology	35
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia	35
Alliance A061202: ixazomib, pomalidomide, and dexamethasone for patients with lenalidomide-refractory MM in first relapse	35
Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials	35
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment	35
Landscape and clinicopathologic features of RAS pathway mutations in chronic myelomonocytic leukemia	35
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy	35
DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma	35
Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E–positive LCH	35
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group	34
Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma	34
Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study	34
Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs	34
JMML tumor cells disrupt normal hematopoietic stem cells by imposing inflammatory stress through overproduction of IL-1β	34
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912	34
World Coalition on SCD launches, sparking global focus on SCD diagnosis and care	34
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population	34
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19–depleted pediatric haploidentical HCT for hematologic malignancy	34
PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma	34
Comments and concerns on the analysis of DAPS-ITP trial	34
Thyroid hormones contribute to JAK/STAT pathway abnormal activation promoting T-cell lymphoma dissemination	33
Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor	33
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms	33
Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study	33
International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL	33
Infection after CD19 chimeric antigen receptor T cell therapy for large B cell lymphoma: Real-world analysis from CIBMTR	33
Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic stem cell transplantation	33
Risk of infectious adverse events of venetoclax therapy for hematologic malignancies: a systematic review and meta-analysis of RCTs	33
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence	33
Pilot study of an inpatient physical activity intervention for older adults treated intensively for acute myeloid leukemia.	33
Thromboprophylaxis in hospitalized and nonhospitalized medical patients: what’s new?	33
Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination	33
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy	33
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial	32
Clinical care pathway for the evaluation of patients with suspected VITT after ChAdOx1 nCoV-19 vaccination	32
Cell-free DNA measurable residual disease as a predictor of postallogeneic hematopoietic cell transplant outcomes	32
Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma	32
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab	32
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML	32
Tarlock K, Gerbing RB, Ries RE, et al. Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Blood Adv. 2024;8(9):2094-2103.	32
Associations between acute and chronic graft-versus-host disease	32
Anticoagulant therapy in patients with congenital FXI deficiency	32
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL	32
Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma	32
HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh	32
Do sophisticated models give the full picture of allogeneic hematopoietic stem cell transplantation effect?	32
Lissitchkov T, Willemze A, Katragadda S, et al. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study. Blood Adv. 2022;6(4):1089-1094.	32
Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM	32
Interactions between integrin α9β1 and VCAM-1 promote neutrophil hyperactivation and mediate poststroke DVT	32
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD	32
Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study	32
Effectiveness and safety of prophylactic anticoagulation among hospitalized patients with inflammatory bowel disease	32
Racial and socioeconomic status diversity and GVHD outcomes	32
Recombinant Erwinia asparaginase (JZP458) in ALL/LBL: complete follow-up of the Children’s Oncology Group AALL1931 study	31
Identification of germline monoallelic mutations in IKZF2 in patients with immune dysregulation	31
Transcriptomic atlas reveals organ-specific disease tolerance in sickle cell mice	31
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey	31
High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention	31
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study	31
Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma	31
Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial	31
Whole genome sequences discriminate hereditary hemorrhagic telangiectasia phenotypes by non-HHT deleterious DNA variation	30
Heightened TLR7 signaling primes BCR-activated B cells in chronic graft-versus-host disease for effector functions	30
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma	30
Mature megakaryocytes acquire immune characteristics in a mouse model of aplastic anemia	30
Cotargeting EBV lytic as well as latent cycle antigens increases T-cell potency against lymphoma	30
Molecular diagnosis of T-cell lymphoma: a correlative study of PCR-based T-cell clonality assessment and targeted NGS	30
Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLs	30
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study	30
Histiocytosis of the orbit and its association with KRAS mutations	29
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study	29
Implementing ASH’s guidelines for acute medical care for incarcerated children and adults with sickle cell disease	29
Characterization and treatment outcomes of malignant histiocytoses in a retrospective series of 141 cases in France	29
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience	29
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity	29
ICANS prophylaxis: potentially transformative but elusive	29
Liver abnormalities are frequent and persistent in patients with Fanconi anemia	29
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel	29
Risk of posthospital venous thromboembolism in patients with COVID-19 varies by SARS-CoV-2 period and vaccination status	29
An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma	29